An Approach to the Treatment of Scleroderma PDF Print E-mail
Wednesday, 03 April 2013 22:30
Systemic sclerosis is unique among the rheumatic diseases because it presents the challenge of managing a chronic multisystem autoimmune disease with a widespread obliterative vasculopathy of small arteries that is associated with varying degrees of tissue fibrosis.

The hallmark of Scleroderma is clinical heterogeneity with subsets that vary in the degree of disease expression, organ involvement, and ultimate prognosis. Thus, the term Scleroderma is used to describe patients who have common manifestations that link them together, whereas a highly variable clinical course exists that spans from mild and subtle findings to aggressive, life-threatening multisystem disease.

The physician needs to carefully characterize each patient to understand the specific manifestations and level of disease activity to decide appropriate treatment. This is particularly important in treating a patient with Scleroderma because there is no treatment that has been proven to modify the overall disease course, although therapy that targets specific organ involvement early before irreversible damage occurs improves both quality of life and survival.

This review describes our approach as defined by evidence, expert opinion, and our experience treating patients.

Scleroderma is a multisystem disease with variable expression; thus, any treatment plan must be holistic, yet at the same time focus on the dominant organ disease. The goal of therapy is to improve quality of life by minimizing specific organ involvement and subsequent life-threatening disease. At the same time the many factors that alter daily function need to be addressed, including nutrition, pain, deconditioning, musculoskeletal disuse, comorbid conditions, and the emotional aspects of the disease, such as fear, depression, and the social withdrawal caused by disfigurement.

To read the full article, please download from the link below.

 
More articles :

» Long Term Methotrexate Therapy Beneficial for Juvenile Localized Scleroderma

Researchers in Italy evaluated 65 patients with Juvenile Localized (JLS; or) previously enrolled in a double blind, randomized control trial and treated for the first 3 months with oral methotrexate (MTX; 15 mg/m2 weekly) and prednisone (1 mg/kg...

» Cell Therapy Yields Promising Results For Scleroderma Treatment

Cytori Therapeutics, Inc. provided preliminary data from a study evaluating a potential treatment for Scleroderma based on the company's cell therapy. The investigator-funded, open-label, pilot study is being conducted on patients with Cutaneous...

» Scleroderma Herbal Treatments

is a connective tissue disease. It causes the skin and internal organs to become hard and tight. This hardening can make it difficult for the sufferer to walk or move and can cause organs to fail. According to the Scleroderma Foundation, in the...

» Rheumatic Autoimmune Diseases: A Local Perspective

Arguably one of the more exciting presentations delivered at the recently concluded , local Rheumatologist Dr. Haramnauth Dyaanand of the Gulf View Medical Centre, delved excitedly into the local context for autoimmune diseases. Starting off largely...

» Knowing When to Get a Second Doctor’s Opinion

Knowing When to Get a Second Doctor’s Opinion. You won’t often hear doctors say it, but medicine is not an exact science. Not all diseases are clear-cut and easy to diagnose. Not all patients with the same condition will experience the same...

» Beta-thymosins and Interstitial Lung Disease: Study of a Scleroderma Cohort with a One-year Follow-up

Beta-thymosins play roles in cytoskeleton rearrangement, angiogenesis, fibrosis and reparative process, thus suggesting a possible involvement in the pathogenesis of systemic sclerosis. The aim of the study was to investigate the presence of...